Drug intelligence / Profile preview

V0116

Development stage: Phase 2
Lead developer: Pierre Fabre
Modality: Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Small Molecules
Administration: Transdermal

Overview

V0116 is a novel transdermal formulation of nicotine developed by Pierre Fabre Medicament. It is currently undergoing clinical evaluation to compare its relative bioavailability and safety profile against existing reference nicotine transdermal patches. The drug is intended for transdermal application.

Brand names: NicopatchLibNicopatch
Other names: V0116 transdermal patchV-0116 transdermal patchV 0116 transdermal patch

Targets

Nicotinic Acetylcholine Receptor

Beyond the preview

Go deeper on V0116.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on V0116.

Explore the full profile